Inhibikase Therapeutics (IKT) EPS (Basic) (QoQ) (2020 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EPS (Basic) (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.46% |
| Mar 31, 2026 | 26.10% |
| Dec 31, 2025 | 1.18% |
| Sep 30, 2025 | -17.82% |
| Jun 30, 2025 | 26.19% |
| Mar 31, 2025 | 70.10% |
| Dec 31, 2024 | 16.89% |
| Sep 30, 2024 | 2.11% |
| Jun 30, 2024 | 11.14% |
| Mar 31, 2024 | 8.66% |
| Dec 31, 2023 | 7.50% |
| Sep 30, 2023 | 24.79% |
| Jun 30, 2023 | -15.41% |
| Mar 31, 2023 | 0.32% |
| Dec 31, 2022 | 3.49% |
| Sep 30, 2022 | 3.13% |
| Jun 30, 2022 | 0.10% |
| Mar 31, 2022 | 33.50% |
| Dec 31, 2021 | -55.70% |
| Sep 30, 2021 | 17.42% |